Qualitative DNA Test Kit for Mycobacterium tuberculosis -MTB and Drug Resistance Mutations - Vietnam Registration 2400519ĐKLH/BYT-HTTB
Access comprehensive regulatory information for Qualitative DNA Test Kit for Mycobacterium tuberculosis -MTB and Drug Resistance Mutations in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loại C medical device is registered under number 2400519ĐKLH/BYT-HTTB and manufactured by Seegene, Inc.. The authorized representative in Vietnam is CÔNG TY TNHH THIẾT BỊ Y TẾ PHƯƠNG ĐÔNG.
This page provides complete technical specifications, regulatory compliance details, 1 companies making similar products including Seegene, Inc., and 1 recent registrations in the same category. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.
Device Details
Registration Details
2400519ĐKLH/BYT-HTTB
20011117/ĐKLH-BYT-TB-CT
Anyplex™ II MTB/MDR/XDR Detection
TB7500Y
Technical Details
Anyplex™ II MTB/MDR/XDR Detection is a qualitative in vitro diagnostic test designed to simultaneously detect Mycobacterium tuberculosis (MTB) and the resistance to first-line anti-tuberculosis drugs (Isoniazid and Rifampicin) and second-line anti-tuberculosis drugs (Fluoroquinolones and injectable drugs) from sputum, culture broth, fresh tissue, or bronchoalveolar lavage fluid samples from symptomatic patients. Drug resistance mutations include: 7 mutations conferring resistance to Isoniazid on the katG gene and the inhA promoter region, 18 mutations conferring resistance to Rifampicin on the rpoB gene, 7 mutations conferring resistance to Fluoroquinolones on the gyrA gene, and 6 mutations conferring resistance to injectable drugs on the rrs gene and the eis promoter region.
Dates and Status
Apr 10, 2024